Evidence map›Paper›PMID 30867375›Full record

ArticleJournal of atherosclerosis and thrombosis2019

Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment.

Hiroyasu Yamamoto, Mari Kawamura, Ikoi Kochi, Minami Imai, Yukie Murata, Toshinobu Suzuki, Yingchao Chen, Kunihiko Hashimoto, Shinji Kihara

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a).Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  2. Article
  3. Anti-Apo B-100 Autoantibody is a Marker of Unstable Coronary Plaque.Journal of atherosclerosis and thrombosis · 2021
    Article
  4. Immunity in Atherosclerosis: Focusing on T and B Cells.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hiroyasu YamamotoDepartment of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
Mari KawamuraDepartment of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
Ikoi KochiDepartment of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
Minami ImaiDepartment of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
Yukie MurataDepartment of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
Toshinobu SuzukiDepartment of Endocrinology and Diabetes in NTT West Osaka Hospital.
Yingchao ChenDepartment of Endocrinology and Diabetes in NTT West Osaka Hospital.
Kunihiko HashimotoDepartment of Endocrinology and Diabetes in NTT West Osaka Hospital.
Shinji KiharaDepartment of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
Osaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIn the pathogenesis of atherosclerosis, autoantibodies have two-facedness of progression and protection. Previous reports have indicated that low autoantibody levels against apolipoprotein B-100 (apo B-100) could increase the risk of atherosclerotic cardiovascular diseases (CVD) in healthy subjects. In this study, we investigated the relationship between circulating anti-apo B-100 autoantibodies and the clinical parameters in Japanese diabetic patients with or without CVD.

methodsWe measured the serum levels of anti-apo B-100 autoantibodies against native and malondialdehyde (MDA)-modified p45 or p210 epitopes, as well as anti-apo E autoantibodies, using enzyme-linked immunosorbent assay.

resultsIn patients with CVD, the circulating levels of IgG against native p45, MDA-modified p45, and MDA-modified p210 (IgG

conclusionMeasurement of serum anti-apo B-100 autoantibodies can be useful for the evaluation of CVD risk in patients with diabetes receiving statin treatment.

Indexed as

AdultAgedAged, 80 and overApolipoprotein B-100AutoantibodiesCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic CardiomyopathiesDisease ProgressionFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrognosisAPOB protein, humanApolipoprotein B-100AutoantibodiesHydroxymethylglutaryl-CoA Reductase InhibitorsApolipoprotein B-100AutoantibodyCardiovascular diseaseDiabetes

Identifiers

PMID30867375
PMCPMC6800396
OpenAlexW2922457437

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.